See what’s new.
Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Uplizna, an antibody therapy for immune diseases, is based on technology licensed from Duke University, developed by the late Dr. Thomas Tedder (Immunology, SOM) and colleagues.
EydisBio Receives FDA Orphan Drug Designation for TAK1 Inhibitor for the Treatment of Systemic Sclerosis
EydisBio is a start-up founded by Professor Timothy Haystead (P&CB, SOM) focusing on the treatment of autoimmune and inflammatory diseases.
Duke Inventions Bring $82.6M in Revenue and Launch 6 New Start-Ups
$82.6M in revenue. 94 patents issued. 302 new invention disclosures. In a down year for new disclosures, OTC focuses on investing in the future.
Sparta Biomedical Reports Treatment of First Patients with Breakthrough Device, Ormi
Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry, Trinity), and colleagues.
Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke
Basking Biosciences, a start-up out of the lab of Professor Bruce Sullenger (Surgery, SOM), is developing a next-generation treatment for acute ischemic stroke.
Adaptin Bio Announces FDA Clearance of IND Application for APTN-101 in Glioblastoma
Adaptin Bio is a Duke start-up based around glioblastoma-related technologies developed in the lab of Dr. John Sampson (Neurosurgery, SOM).
New therapy for glioma receives FDA approval, leveraging cancer research conducted at Johns Hopkins & Duke University
Drs. Darell Bigner and Hai Yan (Neurosurgery, SOM) and colleagues identified the genetic mutation targeted by this new drug. Dr. Katherine Peters (Neurosurgery, SOM) was lead investigator in the clinical trials.
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
Uplizna, an antibody therapy for immune diseases, is based on technology licensed from Duke University, developed by the late Dr. Thomas Tedder (Immunology, SOM) and colleagues.